Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor

被引:93
作者
Filardo, Edward J. [1 ,2 ]
Quinn, Jeffrey A. [1 ,2 ]
Sabo, Edmond [2 ,3 ]
机构
[1] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA
[2] Brown Univ, Sch Med, Providence, RI 02903 USA
[3] Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA
关键词
GPR30; metastasis; estrogen; integrin; EGFR;
D O I
10.1016/j.steroids.2007.12.025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases function as a common signaling conduit for membrane receptors that lack intrinsic enzymatic activity, such as G-protein coupled receptors and integrins. GPR30, an orphan member of the seven transmembrane receptor (7TMR) superfamily has been linked to specific estrogen binding, rapid estrogen-mediated activation of adenylyl cyclase and the release of membrane-tethered proHB-EGF. More recently, GPR30 expression in primary breast adenocarcinoma has been associated with pathological parameters commonly used to assess breast cancer progression, including the development of extramammary metastases. This newly appreciated mechanism of cross communication between estrogen and EGF is consistent with the observation that 7TMR-mediated transactivation of the EGFR is a recurrent signaling paradigm and may explain prior data reporting the EGF-like effects of estrogen. The molecular details surrounding GPR30-mediated release of proHB-EGF, the involvement of integrin beta 1 as a signaling intermediary in estrogen-dependent EGFR action, and the possible implications of these data for breast cancer progression are discussed herein. Published by Elsevier Inc.
引用
收藏
页码:870 / 873
页数:4
相关论文
共 30 条
[1]   Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells [J].
Acconcia, F ;
Barnes, CJ ;
Kumar, R .
ENDOCRINOLOGY, 2006, 147 (03) :1203-1212
[2]   Estrogen and resveratrol regulate rac and cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells [J].
Azios, Nicolas G. ;
Krishnamoorthyy, Lakshmi ;
Harris, Micheleen ;
Cubano, Luis A. ;
Cammer, Michael ;
Dharmawardhane, Surangani F. .
NEOPLASIA, 2007, 9 (02) :147-158
[3]   Identification of Shc as the primary protein binding to the tyrosine-phosphorylated β3 subunit of αIIbβ3 during outside-in integrin platelet signaling [J].
Cowan, KJ ;
Law, DA ;
Phillips, DR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (46) :36423-36429
[4]   Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells [J].
DePasquale, JA .
HISTOCHEMISTRY AND CELL BIOLOGY, 1999, 112 (05) :341-350
[5]   Growth defects induced by perturbation of β1‐integrin function in the mammary gland epithelium result from a lack of MAPK activation via the Shc and Akt pathways [J].
Marisa M Faraldo ;
Marie‐Ange Deugnier ;
Jean Paul Thiery ;
Marina A Glukhova .
The EMBO Reports, 2001, 2 (5) :431-437
[6]   Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires β1 integrin engagement [J].
Festuccia, C ;
Angelucci, A ;
Gravina, GL ;
Eleuterio, E ;
Vicentini, C ;
Bologna, M .
EXPERIMENTAL CELL RESEARCH, 2002, 280 (01) :1-11
[7]   Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression [J].
Filardo, Edward J. ;
Graeber, Carl T. ;
Quinn, Jeffrey A. ;
Resnick, Murray B. ;
Giri, Dilip ;
DeLellis, Ronald A. ;
Steinhoff, Margaret M. ;
Sabo, Edmond .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6359-6366
[8]   GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release [J].
Filardo, EJ ;
Thomas, P .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (08) :362-367
[9]   Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF [J].
Filardo, EJ ;
Quinn, JA ;
Bland, KI ;
Frackelton, AR .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (10) :1649-1660
[10]  
Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966